Evidence that GRIN2A mutations in melanoma correlate with decreased survival

Frontiers in Oncology

Volumn 4 JAN, Issue , 2014, Pages

  D'mello, Stacey Ann N ^a   Flanagan, Jack U ^b,c   Green, Taryn N ^a   Leung, Euphemia Y ^b   Askarian Amiri, Marjan E ^b   Joseph, Wayne R ^b   McCrystal, Michael R ^d,e   Isaacs, Richard J ^f   Shaw, James H F ^g   Furneaux, Christopher E ^d   During, Matthew J ^a,h   Finlay, Graeme J ^b   Baguley, Bruce C ^b   Kalev Zylinska, Maggie L ^a,i  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c MAURICE WILKINS CENTRE FOR MOLECULAR BIODISCOVERY   (New Zealand)

^d AUCKLAND DISTRICT HEALTH BOARD   (New Zealand)

^e Mercy Hospital   (New Zealand)

^f Regional Cancer Treatment Service   (New Zealand)

^g Oncology Surgery Ltd   (New Zealand)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

GluN2A; Glutamate; GRIN2A; Melanoma; Mutation; NMDA receptor; NMDAR; Prognosis

Indexed keywords

ALPHA INTERFERON; B RAF KINASE; DACARBAZINE; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; TUMOR VACCINE; VASCULAR TARGETING AGENT; VINCRISTINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE; GENE MUTATION; GENE SEQUENCE; GENE STRUCTURE; GRIN2A GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MELANOMA; METASTATIC MELANOMA; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PROTEIN FUNCTION; PROTEIN STRUCTURE; SEQUENCE ANALYSIS; VERY ELDERLY;

EID: 84893649181     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00333     Document Type: Article

References (29)

1. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell (2012) 150:251-63. doi: 10.1016/j.cell.2012.06.024
2. Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol (2013) 14:e60-9. doi:10.1016/S1470-2045(12)70539-9
3. Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet (2011) 43:442-6. doi:10.1038/ng.810
4. Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 485:502-6. doi:10.1038/nature11071
5. Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet (2012) 44:1006-14. doi:10.1038/ng.2359
6. Nikolaev SI, Rimoldi D, Iseli C, Valsesia A, Robyr D, Gehrig C, et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet (2012) 44:133-9. doi:10.1038/ng.1026
7. Stark MS, Woods SL, Gartside MG, Bonazzi VF, Dutton-Regester K, Aoude LG, et al. Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat Genet (2012) 44:165-9. doi:10.1038/ng.1041
8. Collingridge GL, Olsen RW, Peters J, Spedding M. A nomenclature for ligand-gated ion channels. Neuropharmacology (2009) 56:2-5. doi:10.1016/j.neuropharm.2008.06.063
9. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev (2010) 62:405-96. doi:10.1124/pr.109.002451
10. Li L, Hanahan D. Hijacking the neuronal NMDAR signaling circuit to promote tumor growth and invasion. Cell (2013) 153:86-100. doi:10.1016/j.cell.2013.02.051
11. North WG, Gao G, Memoli VA, Pang RH, Lynch L. Breast cancer expresses functional NMDA receptors. Breast Cancer Res Treat (2010) 122:307-14. doi:10.1007/s10549-009-0556-1
12. Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch (2010) 460:525-42. doi:10.1007/s00424-010-0809-1
13. Perkinton MS, Ip JK, Wood GL, Crossthwaite AJ, Williams RJ. Phosphatidylinositol 3-kinase is a central mediator of NMDA receptor signalling to MAP kinase (Erk1/2), Akt/PKB and CREB in striatal neurones. J Neurochem (2002) 80:239-54. doi:10.1046/j.0022-3042.2001.00699.x
14. Hoogduijn MJ, Hitchcock IS, Smit NP, Gillbro JM, Schallreuter KU, Genever PG. Glutamate receptors on human melanocytes regulate the expression of MiTF. Pigment Cell Res (2006) 19:58-67. doi:10.1111/j.1600-0749.2005.00284.x
15. Song Z, He C-D, Liu J, Sun C, Lu P, Li L, et al. Blocking glutamate-mediated signalling inhibits human melanoma growth and migration. Exp Dermatol (2012) 21:926-31. doi:10.1111/exd.12048
16. Marshall ES, Matthews JH, Shaw JH, Nixon J, Tumewu P, Finlay GJ, et al. Radiosensitivity of new and established human melanoma cell lines: comparison of [3H]thymidine incorporation and soft agar clonogenic assays. Eur J Cancer (1994) 30A:1370-6. doi:10.1016/0959-8049(94)90188-0
17. Kim JE, Stones C, Joseph W, Leung E, Finlay G, Shelling A, et al. Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines. BMC Cancer (2012) 12:141. doi:10.1186/1471-2407-12-141
18. Ng PC, HenikoffS. Predicting the effects of amino acid substitutions on protein function. Annu Rev Genomics Hum Genet (2006) 7:61-80. doi:10.1146/annurev.genom.7.080505.115630
19. Trevarton AJ, Mann MB, Knapp C, Araki H, Wren JD, Stones-Havas S, et al. MelanomaDB: a web tool for integrative analysis of melanoma genomic information to identify disease-associated molecular pathways. Front Oncol (2013) 3:184. doi:10.3389/fonc.2013.00184
20. Schrodinger LLC. The PyMOL Molecular Graphics System, Version 1.5.0.4 (2010).
21. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol (1993) 234:779-815. doi:10.1006/jmbi.1993.1626
22. Furukawa H, Singh SK, Mancusso R, Gouaux E. Subunit arrangement and function in NMDA receptors. Nature (2005) 438:185-92. doi:10.1038/nature04089
23. Hardingham GE. Coupling of the NMDA receptor to neuroprotective and neurodestructive events. Biochem Soc Trans (2009) 37:1147-60. doi:10.1042/BST0371147
24. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 27:6199-206. doi:10.1200/JCO.2009.23.4799
25. Corp IBM. IBM SPSS Statistics for Windows, Version 19.0. Armonk, NY: IBM Corp (2010).
26. Erreger K, Geballe MT, Kristensen A, Chen PE, Hansen KB, Lee CJ, et al. Subunit-specific agonist activity at NR2A-, NR2B-, NR2C-, and NR2D-containing N-methyl-d-aspartate glutamate receptors. Mol Pharmacol (2007) 72:907-20. doi:10.1124/mol.107.037333
27. Sauna ZE, Kimchi-Sarfaty C. Understanding the contribution of synonymous mutations to human disease. Nat Rev Genet (2011) 12:683-91. doi:10.1038/nrg3051
28. Gartner JJ, Parker SC, Prickett TD, Dutton-Regester K, Stitzel ML, Lin JC, et al. Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc Natl Acad Sci U S A (2013) 110(33):13481-6. doi:10.1073/pnas.1304227110
29. Prickett TD, Samuels Y. Molecular pathways: dysregulated glutamatergic signaling pathways in cancer. Clin Cancer Res (2012) 18:4240-6. doi:10.1158/1078-0432.CCR-11-1217